Literature DB >> 6325711

Rous sarcoma virus p19 and gp35 can be chemically crosslinked to high molecular weight complexes. An insight into virus assembly.

A Gebhardt, J V Bosch, A Ziemiecki, R R Friis.   

Abstract

We have used the method of chemical crosslinking in order to determine the spatial interactions between components of Rous sarcoma virus. A high molecular weight complex formed by crosslinking has been isolated by ultracentrifugation on sucrose density gradients containing 0.1% (w/v) sodium dodecyl sulphate. This complex is composed of the two viral glycoproteins gp85 and gp35, the gag protein p19, and the viral RNA. Two types of bonding are important for the formation and stability of the complex: first, native disulphide bonds between gp85 and gp35 and between individual p19 molecules; and second, hetero-crosslinking between gp35 and p19 as well as homo-crosslinking between p19. Although viral RNA is quantitatively present in the complex, experiments with RNase treatment show that it is not essential for its formation or stability. A small amount of lipid is present in the complex and appears to be crosslinked to p19. In vitro-labelling of purified virus with the lipophilic photoactivatable reagent [125I] iodonaphthylazide resulted in the labelling of gp35 and p19/23. In vivo-labelling of virus with [3H]palmitate resulted in only gp35 becoming labelled. These results substantiate the membrane association of these proteins. The significance of the interactions in the high molecular weight complex for the stability of the virus and, by implication, the role which they may play in viral assembly are discussed.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6325711     DOI: 10.1016/0022-2836(84)90340-1

Source DB:  PubMed          Journal:  J Mol Biol        ISSN: 0022-2836            Impact factor:   5.469


  43 in total

1.  A chimeric avian retrovirus containing the influenza virus hemagglutinin gene has an expanded host range.

Authors:  J Dong; M G Roth; E Hunter
Journal:  J Virol       Date:  1992-12       Impact factor: 5.103

2.  Structural role of the matrix protein of type D retroviruses in gag polyprotein stability and capsid assembly.

Authors:  S S Rhee; E Hunter
Journal:  J Virol       Date:  1990-09       Impact factor: 5.103

3.  Human immunodeficiency virus envelope protein determines the site of virus release in polarized epithelial cells.

Authors:  R J Owens; J W Dubay; E Hunter; R W Compans
Journal:  Proc Natl Acad Sci U S A       Date:  1991-05-01       Impact factor: 11.205

4.  The matrix protein of human immunodeficiency virus type 1 is required for incorporation of viral envelope protein into mature virions.

Authors:  X Yu; X Yuan; Z Matsuda; T H Lee; M Essex
Journal:  J Virol       Date:  1992-08       Impact factor: 5.103

5.  Suppression of retroviral MA deletions by the amino-terminal membrane-binding domain of p60src.

Authors:  J W Wills; R C Craven; R A Weldon; T D Nelle; C R Erdie
Journal:  J Virol       Date:  1991-07       Impact factor: 5.103

6.  The entire SU subunit is required for the incorporation of the HIV-1 envelope glycoprotein complex into virions.

Authors:  Y Y Li; L G Perez
Journal:  Virus Genes       Date:  1997       Impact factor: 2.332

7.  Pseudotyping with human T-cell leukemia virus type I broadens the human immunodeficiency virus host range.

Authors:  N R Landau; K A Page; D R Littman
Journal:  J Virol       Date:  1991-01       Impact factor: 5.103

8.  Role of the matrix protein in the virion association of the human immunodeficiency virus type 1 envelope glycoprotein.

Authors:  T Dorfman; F Mammano; W A Haseltine; H G Göttlinger
Journal:  J Virol       Date:  1994-03       Impact factor: 5.103

9.  The membrane-binding domain of the Rous sarcoma virus Gag protein.

Authors:  M F Verderame; T D Nelle; J W Wills
Journal:  J Virol       Date:  1996-04       Impact factor: 5.103

10.  Gene transfer into mammalian cells by a Rous sarcoma virus-based retroviral vector with the host range of the amphotropic murine leukemia virus.

Authors:  E V Barsov; S H Hughes
Journal:  J Virol       Date:  1996-06       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.